Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Estimation of the public radiation dose from ¹⁷⁷Lu in wastewater discharged by nuclear medicine centers in Tehran, Iran

Document Type : Original Article

Authors
Mohammad Reza Deevband 1
Mohammad Reza Asgari 1
Mahasti Amoui 2
Mohammad Ali Ghodsi Rad 2
1 Biomedical Engineering and Medical Physics Department, School of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran
2 Nuclear Medicine Department, Shohada Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
10.22038/aojnmb.2026.89390.1648
Abstract
Objective(s): Currently, the treatment of prostate and neuroendocrine tumors with radiopharmaceuticals derived from lutetium-177 is the focus of many radionuclide therapy centers. One of the reasons for turning to lutetium radiopharmaceuticals is their favorable dosimetry and stability. Directly excreting the urine of patients treated with these radiopharmaceuticals into the hospital's waste water and consequently into the city's waste water and finally into agricultural fields causes indirect radiation exposure. This study aims to calculate the radiation exposure of people in Tehran due to the presence of this radioactive material in the wastewater of urban areas.
Methods: First, the activity concentration in wastewater was estimated, and then, the dose received by people was estimated via a mathematical model.
Results: The amount of public dose of lutetium in wastewater from nuclear medicine centers in Tehran is 8712.9 nSv/year.
Conclusion: The direct release of patients' urine into the wastewater of nuclear medicine centers in Tehran does not have a significant effect on the radiation exposure of people, and septic tanks are not necessary for these radiopharmaceuticals.
Keywords
Public dose
Lutetium therapy
Prostate cancer
Neuroendocrine tumors
Radionuclide therapy
Subjects
1. Pienta KJ, Esper PS. Risk factors for prostate cancer. Annals of Internal Medicine. 1993; 118(10):793-803.
2.   Kairemo K, Joensuu T. Lu-177-PSMA treatment for metastatic prostate cancer: Case examples of major responses. Clinical and Translational Imaging. 2018; 6(3):223-37.
3.   McBean R, O'Kane B, Parsons R, Wong D. Lu177‐PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. Journal of Medical Imaging and Radiation Oncology. 2019; 63(4): 538-45. 
4.   Iravani A, Violet J, Azad A, Hofman MS. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer and Prostatic Diseases. 2020; 23(1): 38-52.
5.   Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, Van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 2012; 39(Suppl 1): 103-12.
6.   Olmstead C, Cruz K, Stodilka R, Zabel P, Wolfson R. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol. Nuclear Medicine Communications. 2015; 36(2): 129-34.
7.   Andersson M. Radiation dose to patients in diagnostic nuclear medicine. Implementation of improved anatomical and biokinetic models for assessment of organ absorbed dose and effective dose. Lund University; 2017.
8.   Chakraborty A, Mitra A, Tawate M, Sahoo S, Lad S, Rakshit S, et al. Therapeutic multidose preparation of a ready-to-use 177Lu-PSMA-617 using carrier added lutetium-177 in a hospital radiopharmacy and its clinical efficacy. Cancer Biotherapy and Radio-pharmaceuticals. 2021; 36(8): 682-92.
9.   Kinahan A, Hosoda M, Kelleher K, Tsujiguchi T, Akata N, Tokonami S, Currivan L, León Vintró L. Assessment of radiation dose from the consumption of bottled drinking water in Japan. International Journal of Environmental Research and Public Health. 2020; 17(14): 4992.
10. Cousins C, Miller DL, Bernardi G, Rehani MM, Schofield P, Vañó E, et al. International commission on radiological protection. ICRP publication. 2011; 120: 1-25.
11. Vanmarcke H. UNsCEAR 2000: sources of ionizing radiation. Annalen van de Belgische vereniging voor stralingsbescherming. 2002; 27(2): 41-65.
12. Protection R. ICRP publication 103. Annals of the ICRP. 2007; 37(2.4):2.
13. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Journal of medical radiation sciences. 2017; 64(1):52-60.
14. Martin JE, Fenner FD. Radioactivity in municipal sewage and sludge. Public Health Reports. 1997; 112(4): 308. 
15. Jiménez F, López R, Pardo R, Debán L, García-Talavera M. The determination and monitoring of 131I activity in sewage treatment plants based on A2/O processes. Radiation measurements. 2011; 46(1): 104-8.
16. McGowan DR, Pratt BE, Hinton PJ, Peet DJ, Crawley MT. Iodine-131 monitoring in sewage plant outflow. Journal of Radiological Protection. 2014; 34(1): 1-4.
17. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN. Can fluorodihydroxy- phenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Journal of Nuclear Medicine. 2006 47(9): 1455-62.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 14, Issue 2
July 2026
Pages 130-134